We found a 45-kDa novel JAK2 variant that alters kinase domain structure and generates ruxolitinib resistance in Ba/F3 cell line model system without ENU treatment suggesting that novel short form of JAK2 variants need to be analyzed in ruxolitinib resistant MPN patients (52). The gene discussed is JAK2; the disease is myeloproliferative neoplasm.